Healio received an APEX award for a 2024 report on the cloudy future of HIV vaccine research in the age of long-acting ...

Amidst limited doses, priority will be given to those at substantial risk of HIV acquisition, such as adolescent girls and young women who are engaged in marital or concurrent sexual partnerships." ...

Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...

Conference on HIV Science on July 17 in Kigali, one message echoed with urgency across Africa—and especially in Kenya: the global HIV response is at a turning point. IAS 2025 was not just a conference ...

Gilead has partnered with six generic manufacturers to expand access to HIV Drug lenacapavir in high-incidence, resource-limited countries following promising clinical trial results.